FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used for the minimisation of an inflammation in the place of injection in the process of a subcutaneous injection of an anti-CD20 antibody in a concentration, constituting from 100 mg/ml to 200 mg/ml, including the addition of 2% to 30% of cyclodextrin to the composition, containing the said macromolecule. Also claimed are: a pharmaceutical composition for subcutaneous introduction, a method of treating positive B-cell cancer, a method of treating an autoimmune disease, a method of improving or supporting solubility or minimisation of the precipitation of the anti-CD20-antibody in water compositions for subcutaneous introduction in the process of their introduction, a method of increasing the bioavailability of the anti-CD20-antibody, intended for subcutaneous introduction.
EFFECT: group of inventions makes it possible to reduce aggregation, increase bioavailability, minimise inflammation in the place of subcutaneous introduction of the antibody.
48 cl, 7 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| MONOCLONAL ANTIBODIES WHICH SPECIFICALLY BIND TO THE BETA-CHAIN REGION OF THE TRBV-9 FAMILY OF THE HUMAN T-CELL RECEPTOR, AND METHODS FOR USE THEREOF | 2018 |
|
RU2711871C1 |
| SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION | 2007 |
|
RU2487888C2 |
| HUMANISED ANTI-BETA 9 CHAIN ANTIBODIES OF HUMAN TRBV9 TKP FAMILY, AND METHODS OF USING | 2018 |
|
RU2712251C1 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
